Consecutive appearance of corneal subepithelial infiltrates after intravitreous bevacizumab injections.
OBJECTIVE
To report a case of corneal subepithelial infiltrates appearing after intravitreous bevacizumab injections.


METHODS
A review of the patient's history and clinical examination findings in a patient who had epidemic keratoconjunctivitis more then 20 years before treatment with bevacizumab for age-related macular degeneration.


RESULTS
After the third and fourth bevacizumab injections, the patient presented with unilateral corneal subepithelial infiltrates. The infiltrates were accompanied by mild anterior chamber reaction and resolved with topical steroid treatment.


CONCLUSIONS
Treatment with intravitreous bevacizumab may precipitate an immune response leading to the appearance of corneal subepithelial infiltrates.
Bourla
Dan H
DH
Rabin Medical Center, Campus Belinson, Petach Tikva, Israel. danb2@clalit.org.il
Dotan
Assaf
A
Weinberger
Dov
D
Bourla
Nirit
N
Kremer
Israel
I
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D019573:Epithelium, Corneal; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D015745:Granuloma, Foreign-Body / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D012008:Recurrence; D019233:Retreatment; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab